Q-omics provides the consensus-scored PSME4 profile across patient tissues and cancer cell-line models. PSME4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PSME4 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, PSME4 protein abundance shows 26,945 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight ACC, HNSC, and LUAD as cancer lineages where PSME4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PSME4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PSME4 survival associations across molecular data types. PSME4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (10) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PSME4 RNA expression–survival associations across cancer types. High PSME4 expression shows unfavorable associations in ACC, UVM, MESO, KIRP and LGG, but favorable associations in SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PSME4 RNA expression.
This table summarizes PSME4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PSME4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PSME4 shows higher tumor expression in HNSC, LUSC, LIHC, COAD, STAD and LUAD. The HNSC box plot shows higher PSME4 RNA expression in tumor versus normal tissue (log2 FC = +0.974, t-test p < 0.001).
This table shows molecular features associated with PSME4 in patient tissues and cancer cell lines. In patient samples, PSME4 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, PSME4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
